Imperagen, a biotech firm based in Manchester, has secured €5.8 million in Seed funding to enhance its AI and quantum-powered enzyme engineering capabilities. This investment aims to boost research and development, expand laboratory facilities, and strengthen market entry strategies over the next 18 months.
The funding round was spearheaded by PXN Ventures, with contributions from existing investors like IQ Capital and Northern Gritstone, bringing the total capital raised by Imperagen to €9.8 million. The company has appointed Dr. Guy Levy-Yurista as its new CEO, who brings extensive experience in technology and life sciences with a track record of successful exits in both the US and Europe.
Founded in late 2021 as a spin-out from the University of Manchester, Imperagen uses advanced AI techniques to expedite enzyme design, significantly reducing the time and cost associated with traditional methods. The company’s unique approach integrates quantum simulations and AI models tailored to specific engineering challenges, creating a feedback loop that enhances the efficiency and accuracy of enzyme production.
Imperagen’s technology has already yielded impressive results, improving enzyme productivity by as much as 677 times in just a few experimental cycles. As the life sciences sector continues to evolve, the company aims to leverage its innovative platform to meet the demands of various industries, including pharmaceuticals and sustainable chemical production, positioning itself as a significant player in the market.
The infusion of capital will not only facilitate the scaling of its operations but also help in converting increasing commercial interest into revenue, thereby solidifying Imperagen's role in the burgeoning life sciences landscape.